Literature DB >> 35997784

[Public health situation of CIDP patients in nine German centers-neuritis network Germany].

Anna Lena Fisse1, Jeremias Motte2, Thomas Grüter2, Felix Kohle3, Cornelius Kronlage4, Jan-Hendrik Stahl4, Natalie Winter4, Tabea Seeliger5, Stefan Gingele5, Frauke Stascheit6, Benjamin Hotter6, Juliane Klehmet7, Karsten Kummer8, Elena K Enax-Krumova9, Dietrich Sturm10, Thomas Skripuletz5, Jens Schmidt8,11,12, Min-Suk Yoon13, Kalliopi Pitarokoili2, Helmar C Lehmann3, Alexander Grimm4.   

Abstract

BACKGROUND: Diagnosis and treatment of patients with immune-mediated neuropathies is challenging due to the heterogeneity of the diseases.
OBJECTIVES: To assess similarities and differences in the current care of patients with immune-mediated polyneuropathies in specialized centers in Germany within the German neuritis network "Neuritis Netz".
MATERIAL AND METHODS: We conducted a cross-sectional survey of nine neurological departments in Germany that specialize in the care of patients with immune-mediated neuropathies. We assessed the diagnosis, the approach to diagnostic work-up and follow-up, typical symptoms at manifestation and progression of the disease, and treatment data.
RESULTS: This report includes data from 1529 patients per year treated for immune-mediated neuropathies, of whom 1320 suffered from chronic inflammatory demyelinating polyneuropathy (CIDP). Diagnostic work-up almost always included nerve conduction studies, electromyography, and lumbar puncture in accordance with current guidelines. The use of ultrasound, biopsy, and MRI varied. The most important clinical parameter for therapy monitoring in all centers was motor function in the clinical follow-up examinations. A wide range of different immunosuppressants was used for maintenance therapy in about 15% of patients.
CONCLUSIONS: These data provide important epidemiological insights into the care of patients with immune-mediated neuropathies in Germany. The further development of specific recommendations for treatment and follow-up examinations is necessary to ensure a uniform standard of patient care. This effort is greatly facilitated by a structured collaboration between expert centers such as Neuritis Netz.
© 2022. The Author(s).

Entities:  

Keywords:  Chronic inflammatory demyelinating polyneuropathy; Diagnostic criteria; Diagnostics; Patient care; Treatment

Year:  2022        PMID: 35997784     DOI: 10.1007/s00115-022-01377-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.297


  18 in total

1.  Electrophysiologic correlations with clinical outcomes in CIDP.

Authors:  Vera Bril; Marta Banach; Marinos C Dalakas; Chunqin Deng; Peter Donofrio; Kim Hanna; Hans-Peter Hartung; Richard A C Hughes; Hans Katzberg; Norman Latov; Ingemar S J Merkies; Pieter A Van Doorn
Journal:  Muscle Nerve       Date:  2010-10       Impact factor: 3.217

2.  Clinical, Sonographic, and Electrophysiologic Longitudinal Features of Chronic Inflammatory Demyelinating Polyneuropathy.

Authors:  Anna Lena Fisse; Kalliopi Pitarokoili; Nadine Trampe; Jeremias Motte; Antonios Kerasnoudis; Ralf Gold; Min-Suk Yoon
Journal:  J Neuroimaging       Date:  2018-11-08       Impact factor: 2.486

3.  Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Authors:  Russell L Chin; Chunqin Deng; Vera Bril; Hans-Peter Hartung; Ingemar S J Merkies; Peter D Donofrio; Pieter A Van Doorn; Marinos C Dalakas; Norman Latov
Journal:  Muscle Nerve       Date:  2015-07-24       Impact factor: 3.217

4.  Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis.

Authors:  Jeffrey A Allen; John Ney; Richard A Lewis
Journal:  Muscle Nerve       Date:  2017-11-27       Impact factor: 3.217

5.  CIDP diagnostic pitfalls and perception of treatment benefit.

Authors:  Jeffrey A Allen; Richard A Lewis
Journal:  Neurology       Date:  2015-07-15       Impact factor: 9.910

6.  Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Carina Bunschoten; Patricia H Blomkwist-Markens; Anja Horemans; Pieter A van Doorn; Bart C Jacobs
Journal:  J Peripher Nerv Syst       Date:  2019-09-01       Impact factor: 3.494

7.  Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: a survey among Dutch neurologists.

Authors:  Merel C Broers; Pieter A van Doorn; Krista Kuitwaard; Filip Eftimov; Paul W Wirtz; H Stephan Goedee; Hester F Lingsma; Bart C Jacobs
Journal:  J Peripher Nerv Syst       Date:  2020-06-24       Impact factor: 3.494

Review 8.  Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Anna Lena Fisse; Jeremias Motte; Thomas Grüter; Melissa Sgodzai; Kalliopi Pitarokoili; Ralf Gold
Journal:  Neurol Res Pract       Date:  2020-12-08

Review 9.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

10.  Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Max E Adrichem; Ilse M Lucke; Alexander F J E Vrancken; H Stephan Goedee; Luuk Wieske; Marcel G W Dijkgraaf; Nicol C Voermans; Nicolette C Notermans; Catharina G Faber; Leo H Visser; Krista Kuitwaard; Pieter A van Doorn; Ingemar S J Merkies; Rob J de Haan; Ivo N van Schaik; Filip Eftimov
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.